371 related articles for article (PubMed ID: 28370238)
1. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
[TBL] [Abstract][Full Text] [Related]
2. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
[TBL] [Abstract][Full Text] [Related]
3. The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children.
Tesfaye H; Branova R; Klapkova E; Prusa R; Janeckova D; Riha P; Sedlacek P; Keslova P; Malis J
Ann Transplant; 2014 May; 19():214-24. PubMed ID: 24811685
[TBL] [Abstract][Full Text] [Related]
4. Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.
Zao JH; Schechter T; Liu WJ; Gerges S; Gassas A; Egeler RM; Grunebaum E; Dupuis LL
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1471-8. PubMed ID: 25977229
[TBL] [Abstract][Full Text] [Related]
5. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
Lee JW; Kang HJ; Kim S; Lee SH; Yu KS; Kim NH; Jang MK; Kim H; Song SH; Park JD; Park KD; Shin HY; Jang IJ; Ahn HS
Biol Blood Marrow Transplant; 2015 Jan; 21(1):190-5. PubMed ID: 25255163
[TBL] [Abstract][Full Text] [Related]
6. New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning.
Poinsignon V; Faivre L; Nguyen L; Neven B; Broutin S; Moshous D; Bourget P; Dufour C; Dalle JH; Galambrun C; Devictor B; Kemmel V; De Berranger E; Gandemer V; Vannier JP; Jubert C; Bondu S; Mir O; Petain A; Vassal G; Paci A
Pediatr Blood Cancer; 2020 Oct; 67(10):e28603. PubMed ID: 32706505
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
Kletzel M; Jacobsohn D; Duerst R
Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
[TBL] [Abstract][Full Text] [Related]
8. Busulfan dosing in children with BMIs ≥ 85% undergoing HSCT: a new optimal strategy.
Browning B; Thormann K; Donaldson A; Halverson T; Shinkle M; Kletzel M
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1383-8. PubMed ID: 21288495
[TBL] [Abstract][Full Text] [Related]
9. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW
Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611
[TBL] [Abstract][Full Text] [Related]
11. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
Nguyen L; Fuller D; Lennon S; Leger F; Puozzo C
Bone Marrow Transplant; 2004 May; 33(10):979-87. PubMed ID: 15064687
[TBL] [Abstract][Full Text] [Related]
12. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.
Wall DA; Chan KW; Nieder ML; Hayashi RJ; Yeager AM; Kadota R; Przepiorka D; Mezzi K; Kletzel M;
Pediatr Blood Cancer; 2010 Feb; 54(2):291-8. PubMed ID: 19743300
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.
Madden T; de Lima M; Thapar N; Nguyen J; Roberson S; Couriel D; Pierre B; Shpall EJ; Jones RB; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2007 Jan; 13(1):56-64. PubMed ID: 17222753
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic hematopoietic stem cell transplantation as immunotherapy for renal cell carcinoma.
Shaughnessy P; Alexander W; Tran H; Ririe D; Splichal J; Pollack M; Bachier C; LeMaistre C
Mil Med; 2006 Feb; 171(2):161-5. PubMed ID: 16578989
[TBL] [Abstract][Full Text] [Related]
15. Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study.
Ben Hassine K; Nava T; Théoret Y; Nath CE; Daali Y; Kassir N; Lewis V; Bredius RGM; Shaw PJ; Bittencourt H; Krajinovic M; Uppugunduri CRS; Ansari M
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1043-1056. PubMed ID: 34453497
[TBL] [Abstract][Full Text] [Related]
16. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
Lee JW; Kang HJ; Lee SH; Yu KS; Kim NH; Yuk YJ; Jang MK; Han EJ; Kim H; Song SH; Park KD; Shin HY; Jang IJ; Ahn HS
Biol Blood Marrow Transplant; 2012 Jun; 18(6):944-50. PubMed ID: 22155501
[TBL] [Abstract][Full Text] [Related]
17. Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?
Brooks KM; Jarosinski P; Hughes T; Kang E; Shah NN; Gall JBL; Hickstein DD; De Ravin SS; George JM; Kumar P
J Clin Pharmacol; 2018 Mar; 58(3):332-339. PubMed ID: 29238995
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.
Kangarloo SB; Naveed F; Ng ES; Chaudhry MA; Wu J; Bahlis NJ; Brown CB; Daly A; Duggan P; Geddes M; Quinlan D; Savoie ML; Shafey M; Stewart DA; Storek J; Yang M; Zacarias N; Yue P; Magliocco AM; Russell JA
Biol Blood Marrow Transplant; 2012 Feb; 18(2):295-301. PubMed ID: 21801704
[TBL] [Abstract][Full Text] [Related]
19. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.
Le Gall JB; Milone MC; Waxman IM; Shaw LM; Harrison L; Duffy D; van de Ven C; Militano O; Geyer MB; Morris E; Bhatia M; Satwani P; George D; Garvin JH; Bradley MB; Schwartz J; Baxter-Lowe LA; Cairo MS
Bone Marrow Transplant; 2013 Jan; 48(1):19-25. PubMed ID: 22684047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]